Neurovia
2013
FOUNDED
PRIVATE
STATUS
Series A
LATEST DEAL TYPE
$13.9M
LATEST DEAL AMOUNT
5
INVESTORS
Description
Developer of therapies designed to offer treatment for neurological disorders. The company's therapies has developed a selective thyromimetic agent for the treatment of X-linked adrenoleukodystrophy (X-ALD), enabling X-ALD patients to get treatment for their rare genetic disease.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 332 Broadway
- Unit 1
- Cambridge, MA 02139
- United States
+1 (415) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Neurovia’s full profile, request a free trial.
Neurovia Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 25-May-2017 | $13.9M | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
Neurovia Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Neurovia Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Biobrit | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| BioMed Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Enso Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Sanofi-Genzyme Bioventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Neurovia Executive Team (4)
Neurovia Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Giovanni Ferrara | Neurovia | Co-Founder, President, Chief Executive Officer & Board Member | 000 0000 | |
| Henry Skinner Ph.D | Novartis Venture Fund | Board Member | 000 0000 | |
| Jason Hafler Ph.D | Sanofi-Genzyme Bioventures | Board Member | 000 0000 | |
| Thomas Scanlan Ph.D | Neurovia | Founder & Chairman of Scientific Advisory Board | 000 0000 |